Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open- label, phase II trial

Chesney, Jason A.; Puzanov, Igor; Collichio, Frances A.; Singh, Parminder; Milhem, Mohammed M.; Glaspy, John; Hamid, Omid; Ross, Merrick; Friedlander, Philip; Garbe, Claus; Logan, Theodore; Hauschild, Axel; Lebbe, Celeste; Joshi, Harshada; Snyder, Wendy; Mehnert, Janice M.

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open- label, phase II trial

Autor(en):

Chesney, Jason A.; Puzanov, Igor; Collichio, Frances A.; Singh, Parminder; Milhem, Mohammed M.; Glaspy, John; Hamid, Omid; Ross, Merrick; Friedlander, Philip; Garbe, Claus; Logan, Theodore; Hauschild, Axel; Lebbe, Celeste; Joshi, Harshada; Snyder, Wendy; Mehnert, Janice M.

Tübinger Autor(en):

Garbe, Claus

Erschienen in:

Journal For Immunotherapy of Cancer (2023), Bd. 11 (5), Article e006270

Verlagsangabe:

Bmj Publishing Group

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1136/jitc-2022-006270

ISSN:

2051-1426